Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Rating of “Hold” by Brokerages

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have been assigned a consensus rating of “Hold” from the eight research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $5.34.

IRWD has been the subject of several recent analyst reports. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Zacks Research cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Wells Fargo & Company boosted their target price on Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday.

Institutional Trading of Ironwood Pharmaceuticals

A number of institutional investors have recently bought and sold shares of IRWD. Inspire Investing LLC lifted its holdings in shares of Ironwood Pharmaceuticals by 138.3% in the 2nd quarter. Inspire Investing LLC now owns 552,420 shares of the biotechnology company’s stock valued at $396,000 after buying an additional 320,595 shares during the period. Acadian Asset Management LLC grew its holdings in Ironwood Pharmaceuticals by 160.7% during the first quarter. Acadian Asset Management LLC now owns 2,645,189 shares of the biotechnology company’s stock worth $3,878,000 after acquiring an additional 1,630,726 shares during the period. Voleon Capital Management LP raised its position in Ironwood Pharmaceuticals by 952.4% during the first quarter. Voleon Capital Management LP now owns 870,629 shares of the biotechnology company’s stock valued at $1,280,000 after acquiring an additional 787,901 shares in the last quarter. Los Angeles Capital Management LLC raised its position in Ironwood Pharmaceuticals by 76.1% during the second quarter. Los Angeles Capital Management LLC now owns 1,211,155 shares of the biotechnology company’s stock valued at $869,000 after acquiring an additional 523,368 shares in the last quarter. Finally, Focus Partners Advisor Solutions LLC lifted its holdings in Ironwood Pharmaceuticals by 284.6% in the second quarter. Focus Partners Advisor Solutions LLC now owns 39,743 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 29,409 shares during the period.

Ironwood Pharmaceuticals Trading Up 23.3%

Shares of NASDAQ:IRWD opened at $3.86 on Friday. The company has a market capitalization of $627.94 million, a PE ratio of -77.18 and a beta of 0.37. Ironwood Pharmaceuticals has a 12-month low of $0.53 and a 12-month high of $5.13. The business’s fifty day simple moving average is $1.99 and its 200-day simple moving average is $1.25.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Monday, November 10th. The biotechnology company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.15. The business had revenue of $122.06 million during the quarter, compared to the consensus estimate of $74.22 million. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts predict that Ironwood Pharmaceuticals will post 0.1 EPS for the current year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.